The Cytarabine induced Ara-C Ears: A Case Report and Literature Review

Authors

  • Chalisa veerapong Siriraj hospital, Faculty of Medicine, Mahidil University
  • Wasurat Sungworn Faculty of Medicine, Mahidol University
  • Nutnicha Polprasert Faculty of Medicine, Mahidol University

Abstract

Ara-C ears is a variant of toxic erythema of chemotherapy (TEC) presents with erythematous patches or edema on the pinnae of the ear with pain, burning, pruritus, paresthesias and tenderness. It was first reported in 1990 by Krulder et al. This condition cause by cytarabine also known as Ara-C directly toxic to the eccrine duct, the acrosyringium and the epidermis. Ara-C ears is a rare side effect because low density of eccrine gland on the ear.

We report a 39 year-old Thai male with Acute Myeloid Leukemia (AML). He was treated with 3+7 regimen of chemotherapy (cytarabine, idarubicin). He developed erythematous rash on both ears after 5 days of this regimen. He was diagnosed to be Ara-C ears. His symptom was resolve after discontinue cytarabine and supportive treatment with momethasone cream, loratadine and hydroxyzine. Then he was rechallenged with a high dose cytarabine without any symptom. If Ara-C ears is not severe, the chemotherapy will not discontinue. According to the most benefit of patient’s treatment.

Keywords : Cytarabine, Ara-C ears, rash

Author Biographies

Chalisa veerapong, Siriraj hospital, Faculty of Medicine, Mahidil University

Adverse drug reaction unit, Department of Pharmacy, Siriraj Hospital

Wasurat Sungworn, Faculty of Medicine, Mahidol University

Adverse drug reaction unit, Department of Pharmacy, Siriraj Hospital

Nutnicha Polprasert, Faculty of Medicine, Mahidol University

Adverse drug reaction unit, Department of Pharmacy, Siriraj Hospital

References

Krulder JK, Vlasveld LT, Willemze R. Erythema and swelling of ears after treatment with cytarabine for leukemia. Eur J Cancer. 1990;26(5): 649-50.

Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008;59(3): 524-9.

MICROMEDEX®[Database on the internet]. Colorado: Thomson Reuters (Healthcare); c1974-2009. DRUGDEX® System, Cytarabine; [cite 2022 Nov 12]. Available from: http://www.thomsonhc.com. Subscrition required to view.

Cetkovská P, Pizinger K, Cetkovský P. High-dose cytosine arabinoside-induced cutaneous reactions. J Eur Acad Dermatol Venereol. 2002;16(5):481-5.

Anesi GL, Levine D, Attar EC, Fathi AT. Bilateral ear swelling and erythema after chemotherapy: a case of ara-C ears. J Clin Oncol. 2012;30(16):146.

Waseem H, Felipe CH, Hashmi AT, Ansar M, Batool A, Saverimuthu A, et al. Isolated Bilateral Ear and Scalp Rash After Cytarabine Therapy for Acute Myelogenous Leukemia: A Report and Literature Review. Am J Ther. 2019;26(5):653-5.

Jaruvijitrattana P, Chanprapaph K. Bilateral Ear Swelling and Erythema after Chemotherapy: A Case Report of Ara-C Ears. Case Rep Dermatol. 2019;11(2): 226-32.

Doval D, Sharma SK, Kumar M, Khandelwal V, Choudhary D. Cytarabine ears – A side effect of cytarabine therapy. J Oncol Pharm Pract. 2020; 26(2): 471-3.

Ruben BS, Yu WY, Liu F, Truong SV, Wang KC, Fox LP. Generalized benign cutaneous reaction to cytarabine. J Am Acad Dermatol. 2015;73(5): 821-8

Wilke K, Martin A, Terstegen L, Biel SS. A short history of sweat gland biology. Int J Cosmet Sci. 2007;29(3): 169-79.

Cohen PR. Sweet’s syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Diseases. 2007;2:34.

Downloads

Published

2024-08-31